Measuring the Modifiability of Biological Age
The Clock Foundation HLTHSPN study is an observational longitudinal study designed to examine healthspan and biological aging in a diverse cohort of over 1,000 participants, aged 18 to 100.
Our primary goal is to determine the extent to which biological age markers can be rejuvenated through real-world use of existing treatments, lifestyle modifications, and therapeutic interventions.
Study Design
Rolling Enrollment
Join at any time throughout the study period
Quarterly PhenoAge
Blood-based biological age testing every 3 months
Annual GrimAge
DNA methylation epigenetic clock testing yearly
Continuous Wearables
Real-time health monitoring via connected devices
Disease-Specific Cohorts
The HLTHSPN study includes specialized cohorts for conditions where GrimAge shows significant responsiveness to intervention. Join the cohort most relevant to your situation.
High-Impact Interventions
Smoking Cessation
Largest known effect on GrimAge through DNAm Pack Years reversal
Learn moreBariatric Surgery
Document biological age reversal following surgical weight loss
Learn moreSleep Apnea (CPAP)
Track CPAP treatment effects on biological age markers
Learn moreMenopause & HRT
Monitor hormonal transition and HRT effects on aging
Learn moreMetabolic & Treatment Cohorts
Primary Endpoints
Validated biological age measures with proven mortality prediction
GrimAge
Epigenetic DNA Methylation
GrimAge is the gold standard epigenetic clock, analyzing DNA methylation patterns at hundreds of CpG sites. It strongly predicts lifespan, healthspan, and age-related disease onset.
- 81% increased mortality risk per SD increase
- Predicts heart disease, cancer, and cognitive decline
- Validated across diverse populations
- Demonstrated reversibility in intervention studies
PhenoAge
Clinical Biomarker Panel
PhenoAge estimates biological age using 9 routine clinical biomarkers, making it accessible and cost-effective for frequent monitoring of intervention effects.
- Uses standard blood test biomarkers
- Predicts disease onset and mortality
- Fast turnaround for tracking interventions
- Quarterly testing enables trend analysis
Built on Rigorous Science
The HLTHSPN study is grounded in decades of epigenetic aging research, including landmark studies demonstrating the reversibility of biological age markers.
TRIIM Trial (Fahy et al., 2019)
First demonstration of epigenetic age reversal in humans through thymus regeneration
GrimAge Validation (Lu et al., 2019)
Strong prediction of lifespan and healthspan across diverse populations
NU-AGE Mediterranean Diet (Gensous et al., 2020)
Lifestyle intervention demonstrating epigenetic rejuvenation
Study Leadership
Principal Investigator
Robert Brooke, M.Sc. Bioeng.
brooke@clockfoundation.org
Sponsor
Epigenetic Clock Development Foundation
1124 W. Carson St., MRL Bldg, 3rd Floor
Torrance, CA 90502
IRB Oversight
Institute for Regenerative & Cellular Medicine
Santa Monica, CA
Eligibility & Enrollment
Open to adults ages 18-100 across all ethnicities
Inclusion Criteria
- Adults aged 18 to 100 years
- Able to provide informed consent
- Willing to complete survey measures
- Commit to 3+ years of participation
Exclusion Criteria
- Unstable or chronic severe medical conditions
- Severe psychiatric disorders
- BMI greater than 35
- Active alcohol or drug abuse
- Cognitive impairment (MMSE <24)
Join the Healthspan Study
Be part of groundbreaking research to understand and reverse biological aging. Your participation helps advance the science of longevity.
HLTHSPN is an observational research study. This study is conducted under IRB oversight and complies with the Declaration of Helsinki. Participation is voluntary and you may withdraw at any time.